Cosmo has reinvented itself into a recurring-revenue AI-and-dermatology platform—GI Genius and Winlevi are scaling, the balance sheet is fortress-like, and Vision 2030 is the operating-leverage payoff.
Overview
Cosmo Pharmaceuticals N.V. is a transformed mid-cap life sciences company that has shifted from milestone-driven volatility to an innovation-led, high-margin platform anchored in recurring revenues. FY2025 results (published March 9, 2026) show reported revenue of €104.2M—down from €266.8M in 2024 due to a non-recurring €185M Medtronic milestone last year—but the underlying business strengthened: recurring revenue grew 15% to €88.1M and now represents ~85% of the mix. Two assets dominate the growth narrative. GI Genius™ (MedTech AI endoscopy) delivered 211% recurring revenue growth to €17.9M and is evolving toward a higher-margin software/module model (e.g., ColonPRO), supported by platform hardware upgrades and strategic tech partnerships. Winlevi® (acne) generated €17.2M recurring revenue (+27%) and remains the leading branded topical acne treatment in the U.S., with a meaningful European launch planned in 1H 2026 through partners. Cost discipline improved operating leverage: total opex fell 6% and SG&A dropped 26%, enabling EBITDA of €9.5M—above guidance—despite the absence of milestone income; net profit was slightly negative (‑€3.5M). Financial resilience is a key differentiator: €128.3M cash/investments, no debt, and a proposed €2.10/share dividend, plus a non-dilutive treasury-share placement that broadened institutional ownership. The company now frames itself around four pillars—MedTech AI, Dermatology, Gastroenterology, and high-value CDMO—under “Vision 2030,” which targets substantial recurring revenue scaling and materially higher EBITDA as software/royalties expand.